Current and Future Utilization of Optical Genome Mapping: Insights From the 2024 College of American Pathologists Supplemental Questionnaire
This first survey on OGM clinical utilization reveals its status as a niche technology, with 67 laboratories currently using it. Its primary clinical applications are in constitutional/germline analysis and hematologic malignancies. Although international laboratories led in 2024, 108 laboratories (domestic and international) plan clinical adoption within 24 months, signaling OGM's potential for broader integration.
Authors
- Jess F. Peterson (ORCID: https://orcid.org/0000-0003-2496-8000)
- Caroline Astbury (ORCID: https://orcid.org/0000-0001-6741-0010)
- Gopalrao V.N. Velagaleti (ORCID: https://orcid.org/0000-0003-2811-8185)
- Brynn Levy (ORCID: https://orcid.org/0000-0002-4213-3480)
- Rhona J. Souers
- Min Fang (ORCID: https://orcid.org/0000-0003-0431-881X)
- Yang Cao (ORCID: https://orcid.org/0000-0002-2499-3567)
- Guilin Tang (ORCID: https://orcid.org/0000-0002-9482-4806)
- Ying Zou (ORCID: https://orcid.org/0000-0003-2787-1917)
- Juli-Anne Gardner
- Rangsinee Nusapan
- Julian Tan
- James Christopher Mixon
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- College of American Pathologists (US)
- The University of Texas at San Antonio Health Science Center (US)
- Washington University in St. Louis (US)
- Johns Hopkins Medicine (US)
- University of Vermont Medical Center (US)
- University of Illinois Chicago (US)
- Fred Hutch Cancer Center (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Columbia University (US)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2025-11-27
- DOI
- https://doi.org/10.5858/arpa.2025-0472-cp
- Primary Topic
- Genomic variations and chromosomal abnormalities
- Type
- article
- Field-Weighted Citation Impact
- 0.00